February 18, 2014
1 min read
Save

Study: Spine surgery is as cost-effective as total hip or knee arthroplasty for primary osteoarthritis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers found similar 5-year lifetime incremental cost-utility ratios for spinal surgical management and total hip or knee arthroplasty in patients with primary osteoarthritis of the spine, hip or knee.

“Despite a significantly higher revision rate, the overall surgical management of focal lumbar spinal stenosis for those who have failed medical management results in similar median 5-year and lifetime cost-utility compared with those of total hip arthroplasty and total knee arthroplasty for the treatment of osteoarthritis from the limited perspective of a public health insurance system,” the authors wrote in the abstract.

The researchers collected long-term health status data prospectively for surgical outcomes and retrospectively for costs on patients who underwent primary one- to two-level decompression with or without fusion or total hip (THA) or total knee arthroplasty (TKA) for primary osteoarthritis at an average of 5 years follow-up.

Five-year incremental cost-utility ratios (ICURs) were $21,702 per quality adjusted life year (QALY) for THA, $28,595 per QALY for TKA, $12,271 per QALY for spinal decompression without fusion and $35,897 per QALY for spinal decompression with fusion. The lifetime ICURs were $5,682 per QALY for THA, $6,489 per QALY for TKA, $2,994  per QALY for spinal decompression without fusion and $10,806 per QALY for spinal decompression with fusion. Overall, the ICUR for spinal surgery was $5,617 per QALY.

“Surgical management of primary osteoarthritis of the spine, hip and knee results in durable cost-utility ratios that are well below accepted thresholds for cost effectiveness,” the authors wrote.

Disclosure: Rampersaud is a consultant for Medtronic.